Tags : $695M


Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies

Shots: Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s TriNKET technology The agreement is focus on developing and providing immunotherapies using TriNKET technology platform to treat solid malignancies TriNKET technology is based on NK […]Read More